<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Ishizuya Y</submitter><pubmed_abstract>We have reported that the FAN score, which consists of the fibrosis-4 (Fib-4) index, albumin-bilirubin (ALBI) score, and neutrophil-lymphocyte ratio (NLR), is a prognostic marker for patients receiving pembrolizumab for mUC. However, it remains unclear whether the FAN score is a prognostic factor for platinum-based first-line chemotherapy. We included 126 patients with mUC who received platinum-based first-line chemotherapy. The median PFS and overall survival (OS) were 6.3 months (95% confidence interval [CI] 4.5-8.0) and 14.0 months (95% CI 11.1-16.9), respectively. Multivariable analysis showed that Fib-4 index (HR 3.85, 95% CI 1.09-13.58, p = 0.036), ALBI score (HR 1.53, 95% CI 1.01-2.31, p = 0.045), and NLR (HR 1.76, 95% CI 1.14-2.71, p = 0.010) were independently associated with PFS.</pubmed_abstract><journal>Scientific reports</journal><pagination>4640</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11806037</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma.</pubmed_title><pmcid>PMC11806037</pmcid><pubmed_authors>Nonomura N</pubmed_authors><pubmed_authors>Uemura T</pubmed_authors><pubmed_authors>Hayashi T</pubmed_authors><pubmed_authors>Okuda Y</pubmed_authors><pubmed_authors>Kato T</pubmed_authors><pubmed_authors>Yoshimura A</pubmed_authors><pubmed_authors>Yamamichi G</pubmed_authors><pubmed_authors>Oka T</pubmed_authors><pubmed_authors>Tani M</pubmed_authors><pubmed_authors>Ishizuya Y</pubmed_authors><pubmed_authors>Yamamoto Y</pubmed_authors><pubmed_authors>Kawashima A</pubmed_authors><pubmed_authors>Horibe Y</pubmed_authors><pubmed_authors>Nesrine S</pubmed_authors><pubmed_authors>Yamamoto A</pubmed_authors><pubmed_authors>Yutong L</pubmed_authors><pubmed_authors>Hatano K</pubmed_authors></additional><is_claimable>false</is_claimable><name>FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma.</name><description>We have reported that the FAN score, which consists of the fibrosis-4 (Fib-4) index, albumin-bilirubin (ALBI) score, and neutrophil-lymphocyte ratio (NLR), is a prognostic marker for patients receiving pembrolizumab for mUC. However, it remains unclear whether the FAN score is a prognostic factor for platinum-based first-line chemotherapy. We included 126 patients with mUC who received platinum-based first-line chemotherapy. The median PFS and overall survival (OS) were 6.3 months (95% confidence interval [CI] 4.5-8.0) and 14.0 months (95% CI 11.1-16.9), respectively. Multivariable analysis showed that Fib-4 index (HR 3.85, 95% CI 1.09-13.58, p = 0.036), ALBI score (HR 1.53, 95% CI 1.01-2.31, p = 0.045), and NLR (HR 1.76, 95% CI 1.14-2.71, p = 0.010) were independently associated with PFS.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2025-04-04T02:43:16.011Z</modification><creation>2025-04-04T02:43:16.011Z</creation></dates><accession>S-EPMC11806037</accession><cross_references><pubmed>39920103</pubmed><doi>10.1038/s41598-025-86212-7</doi></cross_references></HashMap>